ReviewJournal of human genetics2026
Glycan-related genes and genetic disorders.
Review in Journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An in vivo chemical genetic approach for targeted glycoproteome analysis inbioRxiv : the preprint server for biology · 2026Article
- Medicinal mushrooms and type 2 diabetes: mechanistic insights, translational evidence, and clinical caveats.Frontiers in nutrition · 2026Review
- Decoding sialidase: physiological roles, pathological pathways, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glycosylation is a ubiquitous and essential post-translational modification in biological systems. Most cell-surface and secreted proteins are glycosylated: the glycans contribute to the structural integrity of proteins and cell membranes, and are involved in numerous physiological functions from cell-cell communication and modulation of extracellular signals to immune response and tissue development. The vast array of N-linked, O-linked, and proteoglycan-type glycans are synthesized in a stepwise manner through the coordinated action of numerous glycosyltransferases and glycosidases encoded by "glycogenes". At present, more than 400 glycogenes are involved in glycan biosynthesis in humans. Given the essential roles of glycosylation, it is not surprising that mutations in glycogenes cause various genetic disorders, collectively referred to as congenital disorders of glycosylation (CDGs). However, directly linking specific gene mutations to altered glycan structures and resulting clinical symptoms remains a significant challenge because the biological functions are mediated not by the enzymes themselves, but by the diverse glycan structures that they generate. Many undiagnosed rare diseases are suspected to result from defects in genes involved in glycosylation pathways. Furthermore, reports of newly identified types of CDGs are steadily increasing. Comprehensive understanding of these disorders requires a multidisciplinary approach integrating genetics, biochemistry, glycomics, and clinical research. In this review, we first describe glycans, including the different types and their biological functions. Next, all of the glycogenes involved in various synthetic pathways are presented, followed by examples of genetic disorders caused by their mutation and the glycogenomic approaches used to explore them.
Identifiers
41741713What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.